Andere talen Antengene Corporation Limited

Aandelen

6996

KYG039571008

Vertraagde tijd Hong Kong S.E. Andere beurzen 09:31:45 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,82 ^HKD	+3,80%		-9,89%	-59,00%

22/03	Antengene Corporation Limited rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI
20/03	Antennova voltooit eerste doseringscohort voor Anti-CD24 mAb, ATN-031, in de Fase I PERFORM studie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress across First-in-Class, Best-in-Class Pipeline	25/03
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	20/03
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms	07/03
Antengene Announces Inclusion of XPOVIO in 2023 China's National Reimbursement Drug List	15/12
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	14/12
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List	14/12
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	13/12
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11/12
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	11/12
Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and or Refractory Multiple Myeloma	07/12
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma	06/12
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	06/12
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	20/11
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	17/11
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	17/11
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs	08/11
Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting	01/11
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting	28-09-23
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	22-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Antengene Corporation Limited

Aandelen

6996

KYG039571008

Andere talen

Filters